AlloVir (ALVR) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALVR shares.
View ALVR analyst ratings or view top-rated stocks.

3 brokers have issued twelve-month price targets for AlloVir's shares. Their ALVR share price forecasts range from $17.00 to $20.00. On average, they anticipate the company's share price to reach $18.75 in the next twelve months. This suggests a possible upside of 726.0% from the stock's current price.
View analysts price targets for ALVR or view top-rated stocks among Wall Street analysts.

AlloVir's stock was trading at $5.13 at the beginning of the year. Since then, ALVR stock has decreased by 55.8% and is now trading at $2.27.
View the best growth stocks for 2023 here.

AlloVir saw a increase in short interest in August. As of August 31st, there was short interest totaling 8,310,000 shares, an increase of 7.6% from the August 15th total of 7,720,000 shares. Based on an average daily trading volume, of 868,900 shares, the days-to-cover ratio is presently 9.6 days.
View AlloVir's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ALVR earnings forecast.

AlloVir, Inc. (NASDAQ:ALVR) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.03.

Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD), Cloudera (CLDR), Infinera (INFN), Sonos (SONO), Trevena (TRVN), Abbott Laboratories (ABT), Boeing (BA), Delta Air Lines (DAL), Datadog (DDOG) and FuelCell Energy (FCEL).

(ALVR) raised $252 million in an initial public offering (IPO) on Thursday, July 30th 2020. The company issued 14,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

AlloVir trades on the NASDAQ under the ticker symbol "ALVR."

AlloVir's stock is owned by a number of retail and institutional investors. Top institutional investors include Wasatch Advisors LP (5.84%), Artal Group S.A. (5.79%), BlackRock Inc. (2.92%), Woodline Partners LP (1.52%), American International Group Inc. (1.01%) and JPMorgan Chase & Co. (0.96%). Insiders that own company stock include Agustin Melian, Ann M Leen, Beek Jeroen B Van, Beek Jeroen B Van, Brett R Hagen, David Hallal, Diana Brainard, Edward Miller, Ercem Atillasoy, Gilead Sciences, Inc, Jeffrey S Bornstein, John Robert Wilson, Juan Vera, Morana Jovan-Embiricos and Vikas Sinha.
View institutional ownership trends.

Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALVR stock can currently be purchased for approximately $2.27.

AlloVir (NASDAQ:ALVR) has a market capitalization of $258.48 million. The company earns $-168,710,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis.

The company employs 113 workers across the globe.

AlloVir's mailing address is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. The official website for the company is www.allovir.com. The company can be reached via phone at 617-433-2605 or via email at ir@allovir.com.